Charles River Laboratories Provides Access To Relevant, Well-Characterized Pediatric PDX Collection For Oncology Research
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories International, Inc. (NYSE:CRL) has announced its ability to conduct preclinical cancer research using ITCC-P4's collection of 400 annotated pediatric cancer models. This comes as regulatory guidelines necessitate testing for pediatric indications in oncology research and development. Charles River is offering clients access to this collection, which is critical for research due to the FDA's RACE for Children Act requiring all oncology drugs to be tested for pediatric indications before approval.
October 16, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories' ability to conduct preclinical cancer research using ITCC-P4's pediatric cancer models could potentially increase its client base and revenue. The company's compliance with regulatory guidelines could also enhance its reputation in the industry.
Charles River Laboratories' new ability to conduct preclinical cancer research using pediatric models could attract more clients, especially those focused on pediatric oncology. This could potentially increase the company's revenue. Additionally, the company's compliance with regulatory guidelines could enhance its reputation in the industry, potentially attracting more clients and partnerships.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100